

Drug Monograph

Drug Name: **Drizalma Sprinkle™ (duloxetine delayed-release) capsule**
 Drug Class: **SNRI Agents**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Drizalma Sprinkle capsules are available in 20 mg, 30 mg, 40 mg, and 60 mg capsules.

Manufacturer: Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512

Indications: Drizalma Sprinkle is indicated for 1) Major depressive disorder in adults, 2) Generalized anxiety disorder in adults and pediatric patients 7 years to 17 years old, 3) Diabetic peripheral neuropathic in adults, and 4) Chronic musculoskeletal pain in adults.

Costs: 175.50 per 30 capsules in all strengths Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Jennifer Anderson PharmD, BCPS
 Date: December 29, 2019